Clinical Trial Update: Bortezomib (Velcade) + Pemetrexed (Alimta) in Advanced NSCLC [Phase 1, Phase 2]

View source ↗

Summary

Ongoing Phase 1/2 clinical trial evaluating the combination of bortezomib (Velcade) and pemetrexed (Alimta) in advanced non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alimta (pemetrexed)
• Velcade (bortezomib)

Snippet

Sponsor: Aptium Oncology Research Network | Conditions: Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: UNKNOWN